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Of Babies and Bathwater - The Impact of In
Re Bilski on Life Science Patents
by MICHAEL J. SHUSTER, PH.D., AND JULEEN KONKEL*
I. Introduction
Patents promote innovation by granting inventors the right to
exclude others from practicing their inventions for a limited time.
Patents are granted for ideas that are new, useful, and nonobvious.'
In order to secure patent protection, an inventor must provide a
patent specification that describes the invention, enables a person of
ordinary skill in the art to make and use the invention, and sets forth
the best way the inventor knows or practices the invention.2
The quid pro quo contemplated by the Constitution and by
Congress for granting a patent monopoly is the benefit derived by the
public from an invention with substantial utility. This bargain
between the government and the inventor grants exclusionary rights
in exchange for disclosure and promotes innovation in several ways.'
First, the inventor's disclosure teaches the public how to make and
use the described technology, which becomes freely available once
the patent expires. In addition, the patent system promotes
innovation by creating incentives for others to design around
patented technologies so as to avoid liability for patent infringement.
Patents also promote innovation by providing economic incentives for
investment in new technologies. These exclusive rights allow
* Michael J. Shuster, Ph.D., is a Partner and Co-chair of the Life Sciences Group at
Fenwick & West LLP. Dr. Shuster can be reached at (415) 875-2413, or
mshuster@fenwick.com. Juleen Konkel is a former intellectual property litigation
associate with Fenwick & West. Ms. Konkel can be reached at (415) 867-8459.
1. 35 U.S.C. §§ 101-103 (2006).
2. 35 U.S.C. § 112 (2006).
3. See Michael J. Shuster, Pauline Farmer-Koppenol, and H. Thomas Anderton Jr.,
Observations on Recent Developments in Patent Law: Is the Generic Claim Turning Into an
Endangered Species?, 3 B URRILL PERSONALIZED MED. RPT. 66 (Nov. 2007).
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investors to recoup a fair rate of return by preventing others from
free-riding on their investments.
On the other hand, patents arguably impede innovation. A
dense patent landscape can make it difficult to bring new technologies
to market because royalty payments reduce profit margins to
unattractive levels, or because a required license is unavailable. The
patent system promotes innovation when an appropriate balance is
struck between the scope of available patent protection and the
degree to which that protection advances the art. Accordingly, unless
and until an idea is refined and developed to the point where there is
a specific practical benefit, there is insufficient justification for
permitting an applicant to occupy what may prove to be a broad field.
Recent court cases shed light on what appears to be a
renaissance in redefining the scope of patentable subject matter. The
tension between the broad language of 35 U.S.C. § 101 and the
limitations of its scope by the Supreme Court is often an issue when
determining the patent eligibility of a process. This tension arises
where the process contains a step involving a mathematical algorithm;
however, it is an emerging issue in biotechnology cases where courts
must decide whether the claims preempt a law of nature or a natural
phenomenon. This article summarizes some of the recent changes in
patent law with an emphasis on how the decisions may affect the
ability of personalized medicine companies to protect the technology
behind the products they create.
II. Patentable Subject Matter Under § 101
Congress has broadly defined the subject matter that can be
protected by patent, stating simply, "whoever invents or discovers any
new and useful process, machine, manufacture, or composition of
matter... may obtain a patent..., The 1952 Committee Reports
that accompanied the Patent Act emphasized the breadth of the
statutory subject matter as including "anything under the sun that is
made by man .... "Process," as defined by statute, is synonymous with
"method"' and denotes "an act, or a series of acts, performed upon
the subject-matter to be transformed and reduced to a different state
or thing.",
7
4. 35 U.S.C. § 101 (2006).
5. Diamond v. Diehr, 450 U.S. 175, 182 (1981) (quoting S. REP. No. 82-1979, at 5
(1952)).
6. See 35 U.S.C. § 100(b) (2006).
7. Cochrane v. Deener, 94 U.S. 780, 788 (1876).
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There are several exceptions to this general rule that any process
is eligible for patent protection. It is well established that principles,
such as "natural phenomena, laws of nature, and abstract ideas," are
not patentable under Section 101. However, a process that employs
a law of nature or a natural phenomenon in a useful way may be
protected by patent law. 9 For example, process claims that contain
significant extra-solution activity may transform an unpatentable
principle into a patentable process." Recent case law has attempted
to define the criteria for determining when a process claim combining
unpatentable natural phenomena with significant extra-solution
activity may be patentable under Section 101.
To begin, it is helpful to review those cases that underscore the
federal district courts' approach to analyzing patentable process
claims, starting with the Supreme Court case LabCorp v. Metabolite,
followed by the recent case of Ariad v. Lilly and two cases on appeal
before the Federal Circuit-Classen and Prometheus-and finally the
recent Federal Circuit case In re Bilski.l1
A. The Supreme Court's LabCorp Decision
With each developing technology, the Supreme Court struggles
to define the line separating patentable processes from processes
claiming unpatentable principles of nature or abstract ideas. In
determining what is patentable, the Court must balance the need to
protect and encourage innovation in evolving technologies against
identifying claims that preempt all uses or applications of a newly
discovered idea or principle.
Justice Breyer's dissent in LabCorp v. Metabolite questioned the
proper scope of protection for process claims that embody naturally
existing biological phenomena.12 Metabolite licensed a patent based
8. Diehr, 450 U.S. at 185.
9. Parker v. Flook, 437 U.S. 584, 592 (1978) (distinguishing Morse's invalid claim
broadly covering the use of electromagnetism to print at a distance, from Neilson's valid
claim for a machine applying the principle that heated air increases the intensity of the
heat in a blast furnace).
10. Diehr, 450 U.S. at 192 (significant post-solution activity found where
mathematical formula used to transform or- reduce an article to a different state or thing).
11. See Lab. Corp. of Am. Holdings v. Metabolite Laboratories, Inc., 548 U.S. 124
(2006) [hereinafter "LabCorp"]; In re Bilski, 545 F.3d 943 (Fed. Cir. 2008); Ariad Pharms.
v. Eli Lilly & Co., 529 F. Supp. 2d 106 (D. Mass. 2007), aff'd in part, rev'd in part, 560 F.3d
1366 (Fed. Cir. 2009); Classen Immunotherapies, Inc. v. Biogen IDEC, 381 F. Supp. 2d 452
(D. Md. 2005), aff'd, 2008 U.S. App. LEXIS 25661 (Fed. Cir. Dec. 19, 2008); Prometheus v.
Mayo, No. 04cv1200, 2008 U.S. Dist. LEXIS 25062 at *1 (S.D. Cal. Mar. 28, 2008).
12. LabCorp, 548 U.S. at 125.
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on the discovery of a correlation between high levels of the amino
acid homocysteine and deficiencies in two essential vitamins, folate
and vitamin B12.'3  The patent broadly claimed measuring
homocysteine (i.e., a "homocysteine assay") and the correlation
between the elevated level of homocysteine in the body and a
diagnosis of a deficiency in two essential vitamins (i.e., an "assay and
correlate" claim).14 This correlation is an important test in predicting
the risk for heart disease. The patent seemed to encompass the use of
any methodology for assaying total homocysteine, even assay
techniques developed after the licensing university applied for the
patent. 1
Justice Breyer's dissent argued that the Supreme Court should
have decided whether Metabolite's "assay and correlate" claim was
invalid on the merits because the correlation step claimed a "law of
nature,"'' 6 which, along with natural phenomena and abstract ideas, is
excluded from patent protection. 17 This furthers the patent system's
constitutional mandate to "promote the Progress of Science and
Useful Arts""s by assuring that no monopoly is granted that preempts
the use of a basic scientific fact. According to Justice Breyer, the
correlation claim was little more than a mental step to review the
assay results in light of current medical knowledge.'9 The assay step,
though not specified in the patent claim, was insufficient to remove
the claim as a whole from preempting a natural phenomenon.°
Further, Justice Breyer noted that allowing Metabolite's broad
"assay and correlate" claim to stand expanded the pool of likely
infringers, which may inhibit doctors from using their best medical
judgment and could contribute to healthcare costs. 2 ' Any competent
doctor reviewing the test would automatically correlate the results
with the presence or absence of a vitamin deficiency and thus be
liable as a direct infringer.22  The mental step articulated in the
13. Id. at 128.
14. Id. at 129.
15. Id. at 136.
16. Id. at 132.
17. Id. at 126 (quoting Diehr, 405 U.S. at 185 (1981)).
18. U.S. CONST. art. I, § 8, cl. 8.
19. LabCorp, 548 U.S. at 137.
20. Id. at 137-38.
21. Id. at 138.
22. Metabolite Laboratories, Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1364-
65 (Fed. Cir. 2004). Note that Metabolite has never enforced its patent directly against
physicians.
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correlation claim requires a medical practitioner to consider the
relationship after looking at the test result. 2
B. Post LabCorp Decisions
Breyer's dissent in LabCorp opened the door for challenges to
the validity of claims directed to biological phenomena under Section
101. A series of recent patent decisions have addressed the issue of
whether patent process claims are unpatentable as wholly preempting
natural phenomena or laws of nature.
In the 2007 case Ariad v. Lilly, the district court rejected Lilly's
argument that Ariad's claims embodied a natural phenomenon.24
Directed to the inhibition of a regulatory protein (NF-kB), the '516
patent broadly covers a method of altering the activity of NF-kB in a
cell.25 The claims at issue recite a "reducing" NF-kB activity step, but
do not articulate a particular agent or substance, or any particular
steps, to reduce NF-kB activity in order to practice the invention. "
Lilly argued that the claims encompassed the NK-kB-IkB
autoregulatory loop (the "Autoregulatory Loop"), a natural process
in cells.2  After extensive expert testimony, the district court
concluded the Autoregulatory Loop was an incomplete model, and
that Lilly had failed to meet its evidentiary burden that the
Autoregulatory Loop exists in living cells in the same way it is
encompassed in Ariad's claims.2' Because the Autoregulatory Loop
was an incomplete model that may not exist in nature, the process
claim could not be considered to preempt a "natural phenomenon"
for purposes of Section 101.
Similar to LabCorp, the patents at issue in Classen
Immunotherapies, Inc. v. Biogen IDEC purported to effectively
encompass a naturally existing biological correlation between
variations in a specific vaccination schedule and the risk of developing
23. LabCorp, 548 U.S. at 136.
24. 529 F. Supp. 2d 106 (D. Mass. 2007), aff'd in part, rev'd in part on other grounds,
560 F.3d 1366 (Fed. Cir. 2009).
25. U.S. Patent No. 6,410,516 (filed June 5, 1995) (the '516 patent). Claim 1: A
method for inhibiting expression, in a eukaryotic cell, of a gene whose transcription in
regulated by NF-kB, the method comprising reducing NF-kB activity in the cell such that
expression of said gene is inhibited.
26. Ariad, 529 F. Supp. 2d at 113.
27. Id. at 114-15.
28. Id. at 120.
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chronic immune-mediated disorders. 29 The patents, not specific to a
particular vaccine or vaccine schedule, broadly claimed methods for
determining vaccination protocols based on comparing the incidence
of immune disorders between treatment groups immunized under
different vaccination schedules.3" The district court concluded that
finding a correlation between an immunization schedule and the risk
of developing an immune disorder is a natural phenomenon. 31 The
claims amounted to an "indirect attempt to patent the idea that there
is a relationship between vaccine schedules and chronic immune
mediated disorders. ''32 Further, the Court noted, the active step of
immunizing patients in accordance with a schedule determined to be
low risk was insignificant post-solution activity.3 The court found the
patents invalid for encompassing unpatentable natural phenomena.34
However, Classen did not address the patentability of a field of
use claim restriction, such as whether a biological occurrence that
exists only as a result of human intervention can be accurately
characterized as a natural phenomenon. Such is the issue in
Prometheus v. Mayo, a district court decision, which held that the
correlation between the level of certain metabolites in the blood and
effective therapeutic treatment was a "natural phenomenon.",3' The
patents at issue claimed three steps: (1) administration of the
thiopurine drugs; (2) measurement of the level of certain metabolites
in the blood of patients taking thiopurine drugs to determine the
metabolite level; and (3) correlation of the metabolite level with an
adjustment in drug dosage to avoid toxic side effects. 36 Here,
Prometheus unsuccessfully argued that since the drug metabolites
only exist in the body as the direct result of medical intervention (i.e.,
through the administration of the thiopurine drugs), the correlation is
manmade, not a natural phenomenon.
29. Classen Immunotherapies, Inc. v. Biogen IDEC, 381 F. Supp. 2d 452 (D. Md.
2005).
30. U.S. Patent Nos. 6,420,139 (filed July 6, 2000), Claim 1; 6,638,739 (filed Apr. 18,
2002), Claim 1.
31. Memorandum Order, Classen Immunotherapies v. Biogen IDEC, Civ. No. 04-
2607, p. 10 (D. Md. filed Aug. 16, 2006).
32. Id.
33. Id. at 12.
34. Id.
35. Prometheus v. Mayo, No. 04cv1200, 2008 U.S. Dist. LEXIS 25062 at *1 (S.D. Cal.
Mar. 28, 2008).
36. Prometheus v. Mayo, 2008 U.S. Dist. LEXIS 25062 at *34.
37. Id. at *19.
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The Prometheus court, citing Justice Breyer's dissent in LabCorp
in support of its decision, found the claims of the patents in suit to be
mere correlations resulting from a natural body process;" the court
reasoned that it is the human body that naturally converts the
thiopurine drug into a therapeutic agent through an enzymatic
process. Furthermore, the court found the first two steps of the
patent claims, the "administering" and "determining" steps, merely
necessary "data-gathering steps" used in the subsequent correlation. 4
The court noted that the "data-gathering" steps are insufficient to
make a nonstatutory correlation claim patentable.4' Even though the
patent claims were limited to the level of thiopurine drug in the body,
a field of use limitation, because the inventors did not "create" the
correlation between thiopurine drug metabolite levels and the
therapeutic efficacy and toxicity, the claimed correlation was an
unpatentable "work of nature., 42  This rationale is a significant
obstacle to companies involved in commercializing medical
diagnostics and personalized medicine because these claims
necessarily involve an underlying body process.
These decisions greatly impact the patentability of personalized
medicine inventions that rely on the discovery of the correlation
between biomarkers and the safety and efficacy of therapeutic
treatment in an individual. Although it is unclear what effect
patenting such correlations will have on the development of
personalized medicine, it does appear that in light of these recent
decisions broad personalized medicine patents, and specifically
process claims, face significant challenges under Section 101.
II. The Machine-or-Transformation Test
The Federal Circuit recently clarified one test for determining
patent eligibility of a process under Section 101.43 The machine-or-
transformation test serves as a proxy for assessing whether a process
claim seeks to impermissibly preempt the use of a fundamental
38. Id.
39. Id. at "21.
40. Id. at "17.
41. Prometheus v. Mayo, 2008 U.S. Dist. LEXIS 25062 at *17-18 (citing In re Meyer,
688 F.2d 789, 794 (C.C.P.A. 1982)).
42. Id. at *23 (citing Funk Bros. Seed Co. v. Kalo Inoculant., 333 U.S. 127, 130
(1948)).
43. See In re Bilski, 545 F.3d 943 (Fed. Cir. 2008).
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principle.4  Under the machine-or-transformation test, a claim is
patent eligible if (1) it is tied to a particular machine or apparatus, or1 5
(2) it transforms a particular article into a different state or thing.
To that end, certain criteria must be met under either branch. First,
use of the specific machine or transformation of an article must
convey meaningful limits on the claim's scope to impart patent-
eligibility.46  Second, the involvement of the machine or the
transformation must be central to the claim's purpose and not merely
insignificant extra-solution activity.4
A. The Transformation Test
When not tied to a particular machine or apparatus, the claims
must transform an article into a different state or thing to constitute
patent-eligible subject matter. 4' By definition, a "process" under 35
U.S.C. § 101 requires some kind of transformation or conversion of
subject matter representative of physical activity or objects .
Changes to intangible subject matter representative of physical
activity or objects are also included in this definition.' Prior to Bilski,
the Federal Circuit in In re Abele had defined transformation as it
relates to the Section 101.
In Abele, the Federal Circuit distinguished between two claims,
finding only one to be patentable!s' The unpatentable claim recited a
method of calculating and graphically displaying variances of data
from average values without specifying the type or nature of the data,
how the data was obtained, or what the data represented. 52 The
patentable dependent claim identified the data as "X-ray attenuation
44. Id.
45. Id. at 961.
46. Id. (citing Gottschalk v. Benson, 409 U.S. 63, 71-72 (1972)).
47. Id. at 962; see also In re Grams, 888 F.2d 835, 839-40 (Fed. Cir. 1989) (holding that
a data-gathering step combined with an algorithm, without specifying how the data is to be
gathered, is a meaningless limit on an algorithm claim because every algorithm inherently
requires the gathering of data); In re Schrader, 22 F.3d 290, 293-94 (Fed. Cir. 1994) (claims
directed to a method of conducting an auction, where claims require selecting winning bids
in a manner that maximizes the total price, constitute a mathematical optimization
algorithm, and recording the bids on each item, without describing how, is insignificant
post solution activity).
48. Bilski, 545 F.3d at 961.
49. Schrader, 22 F.3d at 294.
50. Id. at 296.
51. In re Abele, 684 F.2d 902, 909 (C.C.P.A. 1982), abrogated by In re Bilski, 545 F.3d
943 (Fed. Cir. 2008).
52. Abele, 684 F.2d at 908.
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data produced in a two-dimensional field by a computed tomography
scanner." 53 The second claim meaningfully limited the scope of the
patentable claim by identifying what the data represented and
transforming the "raw data into a particular visual depiction of a
physical object on a display. ', s4 In this case, raw data, not the object
itself, was transformed into a graphical display. Because
transformation of the physical object itself is not a requirement of the
transformation test, the claim was patentable. 5'
Furthermore, the Abele patent recited production, detection,
and display steps that, absent the algorithm, resulted in a
conventional CAT scan process.i 6 The court considered the
production and detection steps, which were antecedent to the
algorithm, to be significant pre-solution "data gathering" activity
because the steps were not a requirement of the algorithm but
required by other claim limitations. 7  The resultant display step,
though non-trival post solution activity because it assists in a doctor's
diagnosis, was not the determining factor for patentability.
Unlike the claims in Abele, which transform data representative
of a physical object, the claims at issue in Bilski recited a method
practiced by commodity traders for managing "consumption risk"
associated with the sale of commodities during a given period) 9
Under the claimed method, a commodity trader initiates a series of
swaps with consumers and providers to hedge the price of certain
commodities." Bilski had admitted to a United States Patent and
Trademark Office Examiner that his claims were not limited to
61
operation on a computer.
The Bilski court held that the claims, which were not tied to the
use of a computer, did not involve transformation of an article into a
different state or thing.6' The object of the claims, intangible legal
obligations and other abstractions, were incapable of transformation
53. Id.
54. Id.
55. Bilski, 545 F.3d at 963.
56. Abele, 684 F.2d at 908. Note that the court dissected the claim and evaluated its
patentability on the basis of individual limitations, which is in apparent conflict with the
Supreme Court requiring analysis of the claim as a whole.
57. Id.
58. Id.
59. Bilski, 545 F.3d at 949.
60. Bilski, 545 F.3d at 949.
61. Id. at 950.
62. Id. at 963-64.
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since they did not represent anything tangible.6  The invention
claimed the mental and mathematical process of identifying
transactions that hedge risk, and even though this process required
physical steps of "initiating" and "identifying," these were considered
insignificant post-solution activity, unable to transform an
unpatentable principle into a patentable process' 4  The court
concluded the claims did not constitute patentable subject matter
because they did not involve transformation of an article."6
The Federal Circuit left open the possibility that the
requirements of the machine-or-transformation test could change
upon future developments in technology, and noted that the Supreme
Court may ultimately decide to alter or set aside the test in order to
accommodate emerging technologies.
III. The Impact of Bilski on Biotech Patent Claims
Although Bilski is a "business methods" case, the decision has a
profound effect on biotechnology, specifically medical diagnostics and
personalized medicine patents. The machine-or-transformation test is
only one test for determining whether process claims are eligible for
patent protection, but it is the standard by which biotechnology
claims are currently assessed.
A. Bilski's Impact on Recent and Pending Cases
Take, for example, the claims of the aforementioned Ariad,
Classen, and Prometheus cases. Under the machine-or-
transformation test, the Ariad claim inhibiting gene expression would
be considered patentable subject matter because it involves a
transformation. There is a transformation of the underlying subject
matter, inhibition of gene expression, via the reducing step, which is
tied to level of NF-kB regulatory protein. Although the reducing step
is vague for failing to recite any particular steps or the use of a
particular agent or substance to reduce NF-kB activity, the reducing
step represents a change in a tangible intracellular medium and is
central to the claimed purpose of the invention. Nevertheless, even
though the claims cover a natural body phenomenon and would
therefore be permissible under the machine-or-transformation test,
63. Id.
64. Id. at 965-66.
65. Id.
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they violate the Supreme Court's precedent barring the patenting of
natural phenomena.
On the other hand, the Classen claims would fail the machine-or-
transformation test. The claims in Classen recite methods for
determining optimal immunization schedules based on comparing
incidence of immune-mediated disorders in treatment groups
subjected to different schedules.66 Similar to Bilski, whose legal
obligations were not limited to any specific transactions, the claims in
Classen are not tied to any particular vaccine or vaccine schedule or
to the use of a computer. The mere correlation between a vaccine
and its optimal immunization schedule is not a transformation
because the claim is not tied to anything tangible. The patent does
not claim any specific technique or technical process of testing
vaccine safety and describes only a general inquiry into whether the
proposed correlation even exists. As the Federal Circuit recently
concluded, the machine-or-transformation test invalidates Classen's
claims. 7
Finally, the Prometheus claims would constitute patentable
subject matter because the claims involve a transformation of the
underlying subject matter. The Prometheus claims require both
"administrating" the drug and "determining" the level of the drug
metabolite in the patient. 8 The input is the thiopurine drug; however,
what is being "determined" is not the level of thiopurine drug but the
level of its metabolite in the body. The underlying physical activity is
the injected drug's transformation into quantifiable drug metabolite.
The determining step is then carried out by various unspecified assay
techniques. The "observation" step required in the Prometheus
claims, similar to the "correlate" step in LabCorp, is most likely not
significant post solution activity because it does not alter the
underlying substance in any way. Although the Prometheus claims
technically pass the machine-or-transformation test, the district court
found the claims unpatentable because the correlation between
thiopurine drug metabolite levels and the therapeutic efficacy and
toxicity is considered a natural phenomenon."9
66. Classen Immunotherapies, Inc. v. Biogen IDEC, 2006 U.S. Dist. LEXIS 98106 at
*10 (D. Md. Aug. 16, 2006).
67. Classen Immunotherapies, Inc. v. Biogen IDEC, 2008 U.S. App. LEXIS 25661
(Fed. Cir. Dec. 19, 2008).
68. Prometheus v. Mayo, 2008 U.S. Dist. LEXIS 25062 at *17.
69. Id. at *23.
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However, even if the Federal Circuit were to deem the claims
patentable under the machine-or-transformation test, the claims
could still be invalidated for other reasons. The goal of the
Prometheus claims is to determine the therapeutic dosage in order to
avoid toxic side effects. Measuring the level of drug metabolite in the
body, where the "determining" step is not limited to specific assay
techniques, is obvious and fails for lack of enablement. Further, the
district court found the Prometheus claims invalid solely on the basis
that they claim a natural phenomenon.7" The courts have yet to
reconcile the machine-or-transformation test with the natural
phenomenon doctrine. Thus, even though the claims recite
patentable subject matter under the machine-or-transformation test,
the claims could be invalidated for other reasons.
The impact of Bilski on the aforementioned biotechnology
claims results in a policing of claim scope, a role more commonly
associated with the enablement and written description requirements.
B. Bilski's Impact on Personalized Medicine Claims
The machine-or-transformation test potentially impacts three
classes of biotechnology method claims at the heart of personalized
medicine: (1) the assay-correlate claim, (2) methods of molecular
testing, and (3) methods of treating patients based on specific
polymorphisms or haplotypes.
Personalized medicine and medical diagnostics rely on the
correlation between the presence of biomarkers or level of specific
biomarkers in an individual patient and the safety and efficacy of a
certain therapeutic regime. A personalized medicine diagnostic
employs at least one variable in an interpretive function to yield a
single, patient-specific result (such as "classification," "score," and
"index") for use in the diagnosis of disease or other conditions, or in
the cure, mitigation, treatment, or prevention of disease. These
diagnostics can be used to score or classify patient samples based
upon quantitative predictive modeling using expression values for
single or multiple biomarkers, such as genes, proteins, or
protein/protein interactions as inputs. At the heart of personalized
medicine is the discovery of the correlation between biomarkers and
the efficacy and safety of drugs in an individual.
In terms of biotech and personalized medicine claims, what
constitutes significant extra-solution activity has yet to be addressed
70. Id.
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by the courts. For a process claim to be patentable it must be
distinguishable from the underlying idea. It does appear that a claim
tied to specific assay techniques and therapeutic results would impart
physical steps that meaningfully limit the claim's scope.
Similar to the patentable claim in Abele, personalized medicine
claims require significant quantitative inputs where the data
represents tangible molecular objects, such as genes, expressed
proteins, and physical factors of age, gender, and weight. This raw
data, which is representative of physical matter, is then transformed
into a quantitative score by an algorithm. These claims compile data
points for specific biomarkers, which are transformed into a map
representing the patient's unique phenotypic makeup. The
quantitative score is then used to predict, or correlate, the patient's
risk of disease or the efficacy of a specific therapy. In other words,
personalized medicine assay-correlate claims are not merely the
linear correlation between one biomarker and an in vivo deficiency.
In addition to assay-correlate claims, the personalized medicine
field incorporates methods for molecular testing, such as screening for
different polymorphisms or haplotypes in a target gene or protein.
Polymorphisms are specific genetic allele variants that result in
variations in the functional regions of genes, which include promoter,
enhancer and silencer regions that cause differences in drug response
through effects on the quality or quantity of the drug's target protein.
Haplotypes are combinations of multiple genetically associated
polymorphisms that are inherited as a physically linked block
associated with a responsive or non-responsive phenotype.
Often, claims reciting methods of molecular testing for a specific
polymorphism will also incorporate a method of treatment based on
the responsive or non-responsive phenotype, another variation of the
assay-correlate claim. These claims cover physical objects, not
abstractions, of which representative data is transformed into
information concerning the presence of a polymorphism or haplotype
that incorporates the known functionality of the polymorphism. The
transformation underlying the process is the conversion of
intracellular structures and expressed genes/proteins into
quantifiable, functional data that is specific to the patient creating a
patient specific score. Only once this patient-specific information is
known can a therapeutic treatment be recommended. Under the
machine-or-transformation test, the method of assaying for genetic
polymorphisms or haplotypes the results of which are then correlated
with a specific therapeutic treatment is patentable subject matter.
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Finally, the renewed emphasis on patentable subject matter
raises the question-why? As the legislative history states, Section
101 covers "anything under the sun that is made by man," with a few
limitations.7' The other sections of the patent statute act to limit and
narrow Congress's broad definition of what is patentable subject
matter. In an industry such as personalized medicine, which is
comprised of correlations representative of the underlying body
process, it is difficult to distinguish between claiming a natural body
process that preempts all use of a fundamental principle and those
inventions tailored to unique and novel inventions.
IV. Practical Implications - Claiming Within the New Rules
Personalized medicine diagnostics are being developed that
provide invaluable predictive information for diagnosing or
prognosing heart disease, immunological conditions, or for predicting
whether a patient will respond to treatment using a particular drug.
The information generated by these diagnostics has the potential to
generate enormous savings to the cost of medical care by bringing to
patients more effective, individualized therapies.
Many challenges lie ahead for companies in the biotechnology
field, and the use of Section 101 to challenge a patent's validity is to
be expected. It is therefore critical for personalized medicine
companies to develop and execute patent strategies that anticipate
the possibility of such challenges' eventual success. Should a broad
claim be found invalid under Section 101, a comprehensive set of
dependent claims reciting assay techniques and correlation methods
can provide valuable backup protection. Claims covering
theragnostic technologies (i.e., directed at obtaining a specific test
result and choosing a specific treatment course according to that
result) should be less vulnerable to Section 101 challenges given the
inclusion of another step that necessarily limits such claims so that
they can not fairly be said to preempt a law of nature. And, if
possible, claims should be sought that cover technology used to
obtain patient data, such as, claims direct to specific probes, assays, or
kits.
V. Conclusion
In light of the recent court cases, it appears the courts are
undertaking steps to further define patentable subject matter under
" See supra note 5.
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Section 101. The tension inherent in balancing the broad language of
Section 101 and the limitations on its scope will continue as new
technologies push this boundary. What is certain is that the recent
changes in patent law will affect the ability of personalized medicine
companies to protect the technology behind the products they create.
The advancement of biotechnology and personalized medicine will be
better served by a patent law that identifies the unique specificities of
its industry.
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